

Panel

Daniel A. Ollendorf, PhD

Chief Scientific Officer
Institute for Clinical and Economic Review (ICER)

Robert W. Dubois, MD, PhD

Chief Science Officer and Executive Vice President National Pharmaceutical Council (NPC)

Sara Traigle van Geertruyden, JD

Executive Director
Partnership to Improve Patient Care (PIPC)



Xcenda:



Disclosure

No funding was received for the preparation of this Issues Panel



Value Assessment Landscape

























Personalized medicine, also called precision or individualized medicine, is an evolving field in which physicians use diagnostic tests to identify specific biological markers, often genetic, that help determine which medical treatments and procedures will work best for each patient



Barriers to utilization and value demonstration for personalized medicines



Knowledge and Empowerment	Lack of education and awareness among patients and health care professionals
	Lack of patient empowerment
Value Demonstration	Lack of value recognition (both clinical and economic) and evidence requirements for coverage
	Uncertain evidence requirements for coverage/ reimbursement and other access hurdles
	Access and reimbursement hurdles
Infrastructure	Lack of effective health care delivery infrastructure and information management systems






Value assessment frameworks have the potential to encourage the use of personalized medicine, but that can only happen if frameworks incorporate the elements of personalized medicine that demonstrate its value




Xcenda: **Necessary Considerations for Valuing Personalized Medicines** Incorporation of Diagnostic Testing Emerging or Heterogeneity Evolving of Treatment Value Effects Elements **PATIENT** Individual Treatment Values and Efficiency Circumstance ∭ AmensourceBergen

The question is...







AmerisourceBergen

Where knowledge, reach and partnership shape healthcare delivery.